Business Wire

Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today presented ...

Neurelis to Highlight Data from a Study of Diazepam Nasal Spray in Pediatric Patients at the Child Neurology Society Annual Meeting

Neurelis, Inc., the innovator behind VALTOCO® (diazepam nasal spray), today announced it will present two posters at the 54th ...

Marinus genetic epilepsy drug meets main goal of late-stage study

Marinus Pharmaceuticals Inc said on Monday its experimental treatment for a rare type of genetic epilepsy called CDKL5 deficiency disorder (CDD) met the main goal of reducing seizure frequency in ...